Literature DB >> 20011576

Decreased Use of Antidepressants in Youth After US Food and Drug Administration Black Box Warning.

Tanvir Singh1, Ashwin Prakash, Theodore Rais, Neeta Kumari.   

Abstract

Objective. This study evaluates changes in use of antidepressants in children and adolescents after the US Food and Drug Administration black box warning for increased risk of suicide.Method. A retrospective chart review was completed for children and adolescents (ages 4-17) who were diagnosed with depressive or anxiety disorders in an outpatient clinic and offered a trial of antidepressants between September 2003 and February 2004 (before the black box warning) and between January 2005 and June 2005 (after the black box warning). Statistical analyses were performed with the SPSS version 17 and R package version 2.9.1. Univariate analysis was conducted using the Fisher's Exact test.Results. The odds ratio calculated for the different groups suggests that in all the groups, the proportion of acceptance of antidepressant use was greater before the black box warning as compared to after the black box warning (odds ratio>1). It was also found that upon combining the age groups after the warning and comparing them, based on the diagnoses, there was a greater degree of refusal of antidepressant therapy when a diagnosis of anxiety disorder was made as compared to a diagnosis of depressive disorder (p=0.017).Conclusion. There has been a decrease in the use of antidepressant therapy in children and adolescents following the US Food and Drug Administration black box warning for risk of suicide. A limitation of this study is that reasons for refusal of antidepressent therapy by parents or guardians of children and adolescents were not collected; therefore, there is no certainty that the black box warning was the primary reason for refusal.

Entities:  

Keywords:  FDA; US Food and Drug Administration; adolescent; antidepressant; anxiety; black box warning; child; depression,; suicidality

Year:  2009        PMID: 20011576      PMCID: PMC2790401     

Source DB:  PubMed          Journal:  Psychiatry (Edgmont)        ISSN: 1550-5952


  13 in total

1.  The utilization of antidepressants--a key issue in the prevention of suicide: an analysis of 5281 suicides in Sweden during the period 1992-1994.

Authors:  G Isacsson; P Holmgren; H Druid; U Bergman
Journal:  Acta Psychiatr Scand       Date:  1997-08       Impact factor: 6.392

2.  Suicide risk during antidepressant treatment.

Authors:  Gregory E Simon; James Savarino; Belinda Operskalski; Philip S Wang
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

3.  SSRI prescriptions and the rate of suicide.

Authors:  Mark Olfson; David Shaffer
Journal:  Am J Psychiatry       Date:  2007-12       Impact factor: 18.112

4.  The population impact on incidence of suicide and non-fatal self harm of regulatory action against the use of selective serotonin reuptake inhibitors in under 18s in the United Kingdom: ecological study.

Authors:  Benedict W Wheeler; David Gunnell; Chris Metcalfe; Peter Stephens; Richard M Martin
Journal:  BMJ       Date:  2008-02-14

5.  Suicide and the use of antidepressants. Drug treatment of depression is inadequate.

Authors:  E Isometsä; M Henriksson; M Heikkinen; H Aro; J Lönnqvist
Journal:  BMJ       Date:  1994-04-02

6.  Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States.

Authors:  Charles B Nemeroff; Amir Kalali; Martin B Keller; Dennis S Charney; Susan E Lenderts; Elisa F Cascade; Hugo Stephenson; Alan F Schatzberg
Journal:  Arch Gen Psychiatry       Date:  2007-04

7.  Inadequacy of antidepressant treatment for patients with major depression who are at risk for suicidal behavior.

Authors:  M A Oquendo; K M Malone; S P Ellis; H A Sackeim; J J Mann
Journal:  Am J Psychiatry       Date:  1999-02       Impact factor: 18.112

8.  The relationship between antidepressant prescription rates and rate of early adolescent suicide.

Authors:  Robert D Gibbons; Kwan Hur; Dulal K Bhaumik; J John Mann
Journal:  Am J Psychiatry       Date:  2006-11       Impact factor: 18.112

9.  Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents.

Authors:  Robert D Gibbons; C Hendricks Brown; Kwan Hur; Sue M Marcus; Dulal K Bhaumik; Joëlle A Erkens; Ron M C Herings; J John Mann
Journal:  Am J Psychiatry       Date:  2007-09       Impact factor: 18.112

10.  Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs.

Authors:  Anne M Libby; David A Brent; Elaine H Morrato; Heather D Orton; Richard Allen; Robert J Valuck
Journal:  Am J Psychiatry       Date:  2007-06       Impact factor: 18.112

View more
  13 in total

Review 1.  Impact of safety-related regulatory action on clinical practice: a systematic review.

Authors:  Sigrid Piening; Flora M Haaijer-Ruskamp; Jonie T N de Vries; Menno E van der Elst; Pieter A de Graeff; Sabine M J M Straus; Peter G M Mol
Journal:  Drug Saf       Date:  2012-05-01       Impact factor: 5.606

Review 2.  Unintended Effects of Communicating About Drug Safety Issues: A Critical Review of the Literature.

Authors:  Jessica T DeFrank; Lauren McCormack; Suzanne L West; Craig Lefebvre; Olivia Burrus
Journal:  Drug Saf       Date:  2019-10       Impact factor: 5.606

Review 3.  Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review.

Authors:  Stacie B Dusetzina; Ashley S Higashi; E Ray Dorsey; Rena Conti; Haiden A Huskamp; Shu Zhu; Craig F Garfield; G Caleb Alexander
Journal:  Med Care       Date:  2012-06       Impact factor: 2.983

4.  Treating Pediatric Anxiety: Initial Use of SSRIs and Other Antianxiety Prescription Medications.

Authors:  Greta A Bushnell; Scott N Compton; Stacie B Dusetzina; Bradley N Gaynes; M Alan Brookhart; John T Walkup; Moira A Rynn; Til Stürmer
Journal:  J Clin Psychiatry       Date:  2018 Jan/Feb       Impact factor: 4.384

5.  Ambulatory Fluoroquinolone Use in the United States, 2015-2019.

Authors:  Siddhi Pramod Umarje; Caleb G Alexander; Andrew J Cohen
Journal:  Open Forum Infect Dis       Date:  2021-10-23       Impact factor: 3.835

6.  Selective Serotonin Reuptake Inhibitors (SSRIs) and Their Effect on Patient Aggression in Adult Patients in a State Psychiatric Facility: A Retrospective Analysis.

Authors:  Carolyn O'Donnell; Tammie Lee Demler; Eileen Trigoboff
Journal:  Innov Clin Neurosci       Date:  2022 Jan-Mar

7.  The pharmacoepidemiology of selective serotonin reuptake inhibitors for children and adolescents in Canada from 2005 to 2009: a database analysis.

Authors:  Darren Lam; Daniel A Gorman; Scott Patten; Tamara Pringsheim
Journal:  Paediatr Drugs       Date:  2013-08       Impact factor: 3.022

8.  Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects.

Authors:  Marco Solmi; Michele Fornaro; Edoardo G Ostinelli; Caroline Zangani; Giovanni Croatto; Francesco Monaco; Damir Krinitski; Paolo Fusar-Poli; Christoph U Correll
Journal:  World Psychiatry       Date:  2020-06       Impact factor: 49.548

9.  Dosing of Selective Serotonin Reuptake Inhibitors Among Children and Adults Before and After the FDA Black-Box Warning.

Authors:  Greta A Bushnell; Til Stürmer; Sonja A Swanson; Alice White; Deborah Azrael; Virginia Pate; Matthew Miller
Journal:  Psychiatr Serv       Date:  2015-11-16       Impact factor: 3.084

Review 10.  Pharmacotherapy for anxiety disorders in children and adolescents.

Authors:  Ian Kodish; Carol Rockhill; Chris Varley
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.